TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03727659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHADE therapy + CONNECT FaceBook support
Description: See study arms description.
Study: NCT02673996

Intervention type: DRUG
Intervention: Phenylephrine
Description: incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
Study: NCT02313922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept combined with methotrexate or etanercept combined with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept combined with methotrexate or etanercept combined with placebo
Study: NCT04612803

Intervention type: DRUG
Intervention: Antihistamine
Description: Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
Study: NCT01467661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD422 (anagrelide hydrochloride)
Description: Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
Study: NCT03673956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: 30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
Study: NCT02220361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose dexmedetomidine
Description: received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dexmedetomidine
Description: received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes
Study: NCT04383613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
Study: NCT00588887

Intervention type: DEVICE
Intervention: Duracon®
Description: This group utilizes the Duracon® prostheses for total knee replacement.

Intervention type: DEVICE
Intervention: Vanguard™
Description: This group will utilize the Vanguard™ prostheses for total knee replacement.
Study: NCT03814005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine subcutaneous or intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine subcutaneous or intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine subcutaneous or intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study: NCT04189991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free 02
Description: With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free 02
Description: With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test.
Study: NCT01362699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074
Description: Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral administration. One tablet once daily for 7 days.
Study: NCT03242161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LabPatch-alcohol
Description: a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
Study: NCT00810810

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood components
Description: Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukoreduced blood components
Description: Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukoreduced and irradiated
Description: Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
Study: NCT02645591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)
Description: Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)
Description: Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AmnioFix®
Description: Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
Study: NCT03917082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
Study: NCT04114344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPP
Description: Trans Abdominal Pre Peritoneal approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEP
Description: Total Extra Peritoneal approach
Study: NCT03670901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1101
Description: JHL1101, 100mg/10mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: Rituximab, 100mg/10mL
Study: NCT01501669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Capecitabine
Description: Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
Study: NCT03649516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCKD APP
Description: Use iCKD APP to upload home bio-information data
Study: NCT03819478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss intervention months 0-6
Description: All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss intervention months 0-6
Description: All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss intervention months 0-6
Description: All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention months 0-6
Description: All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
Study: NCT02673996

Intervention type: DRUG
Intervention: Phenylephrine
Description: incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg

Intervention type: DRUG
Intervention: Isoproterenol
Description: incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
Study: NCT01543919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT02673996

Intervention type: DRUG
Intervention: Isoproterenol
Description: incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
Study: NCT00561561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic startle testing
Description: recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic startle testing
Description: recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic startle testing
Description: recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic startle testing
Description: recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
Study: NCT02459548

Intervention type: OTHER
Group type: OTHER
Intervention: Follow up in Sleep Unit Group
Description: Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up in Primary Care Group
Description: Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
Study: NCT03724526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care.
Study: NCT03819478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention months 0-6
Description: All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention months 0-6
Description: All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NutraBio™ CarboMax Supplement
Description: Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 6-month NutraBio™ 100% Whey Protein Isolate Supplement
Description: Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 18-month NutraBio™ 100% Whey Protein Isolate Supplement
Description: Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
Study: NCT05876104

Intervention type: BEHAVIORAL
Intervention: Behavioral therapy
Description: Behavioral and supportive therapy
Study: NCT03745300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATORVASTATIN
Description: Scaling and Root Planing (SRP) followed by placement of atorvastatin gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN
Description: Scaling and Root Planing (SRP) followed by placement of simvastatin gel
Study: NCT00529100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Phase 2
Description: Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Study: NCT00999167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: Part B: 6 mL BID for 16 weeks.
Study: NCT00042289

Intervention type: DRUG
Intervention: atazanavir/cobicistat
Description: atazanavir/cobicistat 300/150 mg q.d.

Intervention type: DRUG
Intervention: atazanavir/cobicistat
Description: atazanavir/cobicistat 300/150 mg q.d.
Study: NCT03745300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Scaling and Root Planing (SRP) followed by placement of placebo gel
Study: NCT01504971

Intervention type: OTHER
Intervention: symptom questionaire
Description: GerdQ questionaire

Intervention type: PROCEDURE
Intervention: pH monitoring
Description: 24-hour pH monitoring

Intervention type: PROCEDURE
Intervention: Tri-modal imaging endoscopy
Description: To investigate WLI,NBI and AFI

Intervention type: DRUG
Intervention: rabeprazole
Description: 10mg, bid, p.o.
Study: NCT02219711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD516
Description: MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
Study: NCT00042289

Intervention type: DRUG
Intervention: atazanavir/cobicistat
Description: atazanavir/cobicistat 300/150 mg q.d.

Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #1
Description: darunavir/ritonavir twice daily 600/100 mg b.i.d.

Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #1
Description: darunavir/ritonavir twice daily 600/100 mg b.i.d.

Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #2
Description: darunavir/ritonavir twice daily 800/100 mg b.i.d.
Study: NCT00999167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part B: same as experimental arm
Study: NCT01411631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape juice polyphenols
Description: Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape juice polyphenols
Description: Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
Study: NCT04047719

Intervention type: DIAGNOSTIC_TEST
Intervention: Karius Test
Description: Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
Study: NCT01672060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Description: Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing services
Description: Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
Study: NCT04629625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: End-range mobilization
Description: End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non end-range mobilization
Description: Non end-range mobilization performed in tibiofemoral joints' loose position

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
Study: NCT03580135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
Study: NCT00585624

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery
Description: Nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No supplement
Description: No supplement
Study: NCT03591159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Membran Sweeping
Description: Cervical Membrane Sweeping by digital examination